Lenvatinib plus pembrolizumab (len+ pembro) showed improved progression-free survival (PFS) and overall survival (OS) compared to chemotherapy in advanced or recurrent endometrial cancer (aEC) in the ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.
Background Breast cancer incidence in women increases with age, while survival rates decrease. Studies interpret this result as meaning higher comorbidity, diagnosis at later stages of the disease ...
During the past 20 years, the advent of neoadjuvant, primary, and adjuvant concurrent chemoradiotherapy has improved cancer care dramatically. Significant contributions have been made by ...
Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein-1 (PD-1), and programmed cell death ligand-1 (PD-L1) have been approved for a variety of malignant tumors and are widely ...
Overall, the open-label phase 1/2 study is assessing the safety and anti-tumor activity with INKmune across 3 dose levels. “The key here is I don’t believe that testosterone increases the risk of ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback